P704: The effect of antiTNFα and anti-integrin agents on liver steatosis in inlamatory bowel disease patients with non-alcoholic fatty liver diseaseECCO’23 CopenhagenYear: 2023
Authors: Mitrovic, M.(1)*;Marković, S.(1);Kalaba, A.(2);Zarić, D.(1);Kralj, Đ.(1);Milić, A.(2);Svorcan, P.(1);
(1)University Medical Center Zvezdara, Department of Gastroenterology, Belgrade, Serbia;(2)University Medical Center Zvezdara, Departement of Gastroenterology, Belgrade, Serbia;
P705: Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomesECCO’23 CopenhagenYear: 2023
Authors: Nowell, E.(1);Laird, S.(1);Bailey, E.(1);Brownson, E.(1)*;Saunders, J.(1);Seenan, J.P.(1);Smith, G.(1);Macdonald, J.(1);
(1)NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom;
P706: Monitoring asymptomatic patients with Crohn's disease: the role of intestinal ultrasoundECCO’23 CopenhagenYear: 2023
Authors: Dussias, N.(1)*;Melotti, L.(1);Mazzotta, E.(1);Decorato, A.(1);Vanigli, N.(1);Rizzello, F.(1);Gionchetti, P.(1);
(1)IRCCS Azienda Ospedaliero-Universitaria Policlinico S. Orsola - Malpighi, Department of Medical and Surgical Sciences, Bologna, Italy;
P707: Using urgent small bowel ultrasound (SBUS) as a tool for decision-making in patients with inflammatory bowel disease (IBD): retrospective analysis of United Kingdom (UK) patients' outcome.ECCO’23 CopenhagenYear: 2023
Authors: Lehmann, A.(1)*;Nandra, G.(2);Power, N.(2);Lindsay, J.O.(1);
(1)Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(2)Barts Health NHS Trust, Radiology, London, United Kingdom;James Oliver Lindsay
P708: Post-COVID-19 and Quality of Life in Patients with Immune Mediated Inflammatory DiseasesECCO’23 CopenhagenYear: 2023
Authors: Schlosser, T.(1)*;Krasselt , M.(2);Elsing, L.(1);Hecker, M.(1);Holler, B.(1);Hoffmeister, A.(1);
(1)University Medical Centre Leipzig, Department of Oncology- Gastroenterology- Hepatology- Pulmonology and Infectious Diseases- Division of Gastroenterology, Leipzig, Germany;(2)University Medical Centre Leipzig, Department of Endocrinology- Nephrology and Rheumatology- Division of Rheumatology, Leipzig, Germany;
P709: Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn's disease of the small intestineECCO’23 CopenhagenYear: 2023
Authors: Viazis, N.(1)*;Koustenis, K.(1);Veretanos, C.(1);Mountaki, A.(1);Almpani, F.(1);Tsatsa, A.(1);Trikola, A.(1);Beka, H.(1);Arvanitis, K.(1);Georgiadi, T.(1);Nousias, G.(1);Mylonas, I.(1);Kozompoli, D.(1);Paparizou, N.(1);Karaouzas, L.(1);Papastergiou, V.(1);Archavlis, E.(1);Mela , M.(1);Christidou, A.(1);Varytimiadis , K.(1);Hatzievangelinou, C.(1);Katopodi, K.(1);Vienna, E.(1);Mantzaris, G.(1);
(1)Evangelismos Hospital, Gastroenterology, Athens, Greece;
P710: Changes of gut microbiome after anti-TNF-α therapy and the prediction of clinical remission in patients with active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: ShinShin, S.(1)*;Oh, H.N.(2);Moon, J.M.(1);Joo, H.J.(1);Sul, W.J.(2);Choi, C.H.(1);
(1)Chung-Ang University College of Medicine, Department of Internal medicine, Seoul, Korea- Republic Of;(2)Chung-Ang University, Department of Systems Biotechnology, Anseong, Korea- Republic Of;
P711: Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.ECCO’23 CopenhagenYear: 2023
Authors: Yeo, G.D.D.(1)*;Qui, M.(2);Pak, W.C.W.(1);Tan, C.K.(3);Tay, S.W.(1);Lim, C.T.T.(1);Tan, T.K.M.(1);Ong, W.C.(4);Lim, T.G.(4);Ng, Y.T.V.(4);Wong, S.Y.A.(4);Salazar, E.(1);
(1)Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(2)Duke-NUS Medical School, Programme in Emerging Infections Disease, Singapore, Singapore;(3)Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore;(4)Singapore General Hospital, Department of Pharmacy, Singapore, Singapore;
P713: Proactive therapeutic infliximab monitoring during induction phase in inflammatory bowel diseaseECCO’23 CopenhagenYear: 2023
Authors: Gonzalez Vivo, M.(1,2)*;Carballo Martinez, N.(2,3);Padulles Zamora, N.(4);Colominas Gonzalez, E.(2,3);Murciano Gonzalo, F.(1);Abril Rodriguez, L.(1);Marquez-Mosquera, L.(1,2);
(1)Hospital del Mar, Gastroenterology department, Barcelona, Spain;(2)IMIM, Hospital del Mar Medical Research Institute, Barcelona, Spain;(3)Hospital del Mar, Pharmacy department, Barcelona, Spain;(4)Hospital Universitari de Bellvitge, Pharmacy department, L'Hospitalet de Llobregat, Spain;
P714: Mucosal healing in CD with vedolizumab versus other biologics: endoscopic outcomes during long-term routine care in a multinational observational studyECCO’23 CopenhagenYear: 2023
Authors: Siegel, C.(1)*;Sebastian, S.(2);Siegmund, B.(3);Zhou, J.(4);Jones, S.(5);Adsul, S.(4);Louis, E.(6);
(1)Dartmouth Hitchcock Medical Center, Gastroenterology and Hepatology, Lebanon- NH, United States;(2)Hull University Teaching Hospital, IBD Unit, Hull, United Kingdom;(3)Charité – Universitätsmedizin Berlin- Campus Benjamin Franklin, Medical Department- Division of Gastroenterology- Infectiology and Rheumatology-, Berlin, Germany;(4)Takeda, Gastroenterology, Cambridge- MA, United States;(5)Takeda, Gastroenterology, Zurich, Switzerland;(6)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;
P715: Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Colombel, J.F.(2);Rubin, D.T.(3);Ghosh, S.(4);Jain, A.(5);Lawlor, G.(5);Osterman, M.T.(5);Wu, H.(5);Canavan, J.B.(5);Chiorean, M.V.(6);
(1)University of Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago, United States;(4)University of Birmingham- Birmingham, Immunology and Immunotherapy, Birmingham, United Kingdom;(5)Bristol Myers Squibb, Clinical Research, Princeton, United States;(6)Swedish Gastroenterology, Gastroenterology, Issaquah, United States;
P716: A 2-week course of Exclusive Enteral Nutrition followed by the Crohn Disease Exclusion Diet is effective for Induction and Maintenance of Remission in children with Crohn Disease; the DIETOMICS-CD trialECCO’23 CopenhagenYear: 2023
Authors: Sigall-Boneh, R.(1,2)*;Manuel Navas-López, V.(3); Hussey, S.(4);Pujol Muncunill, G.(5);Lawrence, S.(6);Jonsson Rolandsdotter, H.(7,8);Otley, A.(9);Martín-de-Carpi5, J.(5);Abramas, L.(1);Herrador López , M.(10);Egea Castillo, N.(11);Chen, M.(12);Hurley, M.(13);Wingate, K.(14);Olen, O.(15,16);yaakov, M.(1);Levine, A.(1,17);Van Limbergen, J.(18,19);Wine, E.(12);
(1)The E. Wolfson Medical Center, Paediatric Gastroenterology and Nutrition Unit, Holon, Israel;(2)Tel-Aviv University, The Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Hospital Regional Universitario de Málaga, Paediatric Gastroenterology and Nutrition Unit-, Málaga, Spain;(4)Royal College of Surgeons of Ireland and University College Dublin, National Children's Research Centre, Dublin, Ireland;(5)Hospital Sant Joan de Déu, Paediatric Gastroenterology- Hepatology and Nutrition Department., Barcelona, Spain;(6)BC Children's Hospital- University of British Columbia- BC, Paediatric Gastroenterology, Vancouver-, Canada;(7)Södersjukhuset- Karolinska Institutet- 11883, Department of Clinical Science and Education-, Stockholm, Sweden;(8)Sachs' Children and Youth Hospital- Södersjukhuset- 11883, Department of Gastroenterology, Stockholm-, Sweden;(9)IWK Health Center- - NS B3K 6R8, Division of Gastroenterology and Nutrition-, Halifax, Canada;(10)Hospital Regional Universitario de Málaga, Paediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(11)Hospital Sant Joan de Déu, Paediatric Gastroenterology- Hepatology and Nutrition Department., - Barcelona, Spain;(12)University of Alberta, Departments of Paediatrics and Physiology, Edmonton, Canada;(13)Children's Health Ireland - Crumlin, Children's Health Ireland, Dublin, Ireland;(14)BC Children's Hospital- University of British Columbia - BC, Paediatric gastroenterology, Vancouver, Canada;(15)Sachs' Children and Youth Hospital- Södersjukhuset- 11883, Department of Gastroenterology, Stockholm, Sweden;(16)Karolinska Institutet., Clinical Epidemiology Division- Department of Medicine Solna-, Stockholm, Sweden;(17)Tel Aviv University, 2. The Sackler Faculty of Medicine, Tel Aviv, Israel;(18)Amsterdam University Medical Centers- Emma Children's Hospital, Division of Paediatric Gastroenterology and Nutrition- Department of Pediatrics, Amsterdam, Netherlands Antilles;(19)Tytgat Institute for Liver and Intestinal Research- Academic Medical Center- University of Amsterdam, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam, Netherlands Antilles;
P717: Use of tramadol versus traditional opioids and adverse outcomes of Inflammatory Bowel Diseases: a Danish nationwide cohort studyECCO’23 CopenhagenYear: 2023
Authors: Dalal, R.(1)*;Lund, K.(2);Zegers, F.(2);Friedman, S.(1);Allegretti, J.(1);Norgard, B.(2);
(1)Brigham and Women's Hospital- Harvard Medical School, Gastroenterology- Hepatology and Endoscopy, Boston, United States;(2)Odense University Hospital, Clinical Epidemiology, Odense, Denmark;
P718: A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Otero Piñeiro, A.(1)*; Lightner , A.L.(1);Reese , J.(2);Ream , J.(3);Nachand , D.(4);Adams , A.(5);VanDenBossche, A.(1);Kurowski, J.(6);
(1)Digestive Disease Surgical Institute- Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, National Center for Regenerative Medicine, Cleveland, United States;(3)Digestive Disease Surgical Institute- Cleveland Clinic, Department of Abdominal Radiology-, Cleveland, United States;(4)Digestive Disease Surgical Institute- Cleveland Clinic, Department of Abdominal Radiology, Cleveland, United States;(5)Digestive Disease Surgical Institute- Cleveland Clinic, Department of Colorectal Surgery, Cleveland, United States;(6)Pediatric Institute- Cleveland Clinic, Pediatrics, Cleveland, United States;
P719: Symptomatic improvement and long-term stability of ulcerative colitis symptoms over 3 years of ozanimod treatmentECCO’23 CopenhagenYear: 2023
Authors: Danese, S.(1)*;Abreu, M.T.(2);Afzali, A.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Panaccione, R.(5);Wolf, D.C.(6);
(1)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(2)University of Miami Miller School of Medicine, Medicine, Miami, United States;(3)University of Cincinnati College of Medicine, Medicine, Cincinnati, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)Inflammatory Bowel Disease Clinic, Medicine, Calgary, Canada;(6)Atlanta Gastroenterology Associates LLC, Medicine, Atlanta, United States;
P720: Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CAREECCO’23 CopenhagenYear: 2023
Authors: Hanzel, J.(1)*;Supovec, E.(2);Smrekar, N.(1);Koželj, M.(1);Kurent, T.(1);Štabuc, B.(1);Novak, G.(1);Drobne, D.(1);
(1)University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia;(2)University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia;SING (Slovenian National IBD Study Group)
P722: Symptom-based disease trajectories Identify a population of early super-responders in ulcerative colitis achieving complete disease control under targeted therapyECCO’23 CopenhagenYear: 2023
Authors: Tran, F.(1,2)*;Brard, R.(3);Flechsenhar, K.(4);Aden, K.(1,2);Rosenstiel, P.(2);Agueusop, I.(3);Schreiber, S.(1,2);
(1)University Medical Center Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)University Medical Center Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany;(3)Sanofi, Biostatistics & Programing- Early Development & Research Statistics, Frankfurt am Main, Germany;(4)Sanofi, Immunology and Inflammation Therapeutic Area- Type 1/17 Immunology Cluster, Frankfurt am Main, Germany;
